Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HELP with free AI briefings, catalyst countdowns, and dilution alerts.

HELP · Helus Pharma Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$166.4M Cash on Hand
14.2mo Cash Runway
0% Short Interest
$45.84 Analyst Target (10)
Follow HELP by email Get an email when HELP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HELP, unsubscribe in one click. Privacy

📣 What HELP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CYB003 Major Depressive Disorder (MDD) Phase 3 · NCT06793397 Recruiting
CYB004 Generalized Anxiety Disorder Phase 2 · NCT06051721 Completed
Psilocybine Depression Phase 2 · NCT05594667 Withdrawn

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HELP holds $166.4M in cash and short-term investments and burns about $35.2M/quarter from operations, an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HELP files for a raise →

👥 Who Owns HELP

Insiders 49.5% Institutions 50.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Adage Capital Management, L.P. Institution (13G, 5%+) 5,479,250 25.37% 2026-09-30
Adage Capital Partners GP L.L.C. Institution (13F) 5,250,000 24.30% 2026-09-30
Eric H. L. So
Director
Insider 4,766,630 22.07% 2026-09-30
Paul Glavine
Chief Growth Officer, Director
Insider 4,750,191 21.99% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 2,849,565 13.19% 2026-09-30
Acorn Capital Advisors, LLC Institution (13F) 1,540,266 7.13% 2026-09-30
Rosalind Advisors, Inc. Institution (13F) 1,387,969 6.43% 2026-09-30
Two Sigma Investments, LP Institution (13F) 1,339,912 6.20% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 1,268,394 5.87% 2026-09-30
Point72 Asset Management, L.P. Institution (13F) 1,229,137 5.69% 2026-09-30
DCF Advisers, LLC Institution (13F) 1,002,600 4.64% 2026-09-30
Nan Fung Group Holdings Limited Institution (13F) 987,222 4.57% 2026-09-30

Share count 21,601,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-30
filed 2026-10-01
So Eric H. L.
Award (A) 248,000 – 4,713,014
2026-09-30
filed 2026-10-01
Glavine Paul
Award (A) 248,000 – 4,750,191
2026-09-29
filed 2026-10-01
Cavers Greg
Purchase (P) 3,000 $12.91 3,000

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full HELP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HELP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.